Patients treated with a GLP-1 RA were younger, more likely obese and with HFrEF, had significantly lower levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), with a history of ischaemic heart disease, renal impairment, a longer duration of T2DM and a worse glycaemic control (i.e. higher prevalence of retinopathy and albuminuria), and higher education level and income compared with patients not on GLP-1 RA (Table 1). The gene discussed is GLP1R; the disease is retinal disorder.